Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of ginsenoside in making medicine

A technology for preparing ginsenosides and drugs, which can be used in drug combinations, pharmaceutical formulas, medical preparations containing active ingredients, etc., and can solve problems such as enhancing memory

Inactive Publication Date: 2003-11-26
上海复旦金科生物技术有限公司
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] In summary, there is no report in this field about the use of ginsenosides to resist brain aging and nerve cell damage and enhance memory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of ginsenoside in making medicine
  • Use of ginsenoside in making medicine
  • Use of ginsenoside in making medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1 The effects of ginsenosides on the survival and growth of human cerebral cortical neuronal cell lines were detected by cell biology

[0052] 1. Materials and methods

[0053] experimental cells

[0054] In vitro cell culture of human cerebral cortical neurons HCN-1A.

[0055] Ginsenosides (selected from Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, Rg2, Rg3, Rh1, Rh2, Ro or their mixtures) were prepared into a 1g / m1 concentration stock solution for later use.

[0056] Neural cell culture: culture system DMEM (Gibco) containing EGF 2u / ml, calf serum 10%, cells 4×10 5 / ml, 37°C, 5% CO 2 Cultivated in an incubator.

[0057] 2. Effects of ginsenosides on the growth of nerve cells under the condition of low calf serum

[0058] Cells were collected, inoculated into 50 dishes, and two groups were set up with ginsenosides (10 μg / ml) and without ginsenosides. The culture was continued, the calf serum was reduced to 2%, and the culture system DMEM (Gibco) contained EGF 2u / ml. O...

Embodiment 2

[0075] Example 2 Using gene chip to study the effect of ginsenosides on gene expression patterns of human cerebral cortical neuronal cell lines

[0076] 1. Materials and methods

[0077] Chip preparation

[0078] The 12,000 full-length known gene cDNAs used in the chip were amplified by PCR with universal primers, and the length of PCR products was 1000±50 bp (with a few exceptions). PCR reactions and product purification were performed using standard methods, and PCR quality was monitored by agarose electrophoresis. The target gene was dissolved in 3×SSC solution, and spotted by SpotBotTM Personsl Microarrayer of TeleChem Company and silanized glass slide. After spotting, the slides were hydrated (2hr), dried at room temperature for 10min, UV cross-linked (energy value was set to 60mj / cm), then treated with 100% alcohol for 30 seconds, and dried for use.

[0079] processing of cells

[0080] In the experiment, the human cerebral cortical nerve cells HCN-1A cultured in vit...

Embodiment 3

[0120] Example 3 Animal experimental research report on anti-aging of ginsenosides

[0121] group of experimental animals

[0122] There were 18 four-month-old male Wistar rats, weighing 265±36g. They were randomly divided into three groups: control group, brain aging group and brain aging administration group, with 6 animals in each group.

[0123] Establishment and drug administration of brain aging model

[0124] Brain senescence was induced by subcutaneous injection of 2 ml of D-galactose (48 mg / kg.d).

[0125] Brain aging group Subcutaneous injection of D-galactose (48mg / kg.d) for 6 weeks

[0126] Subcutaneous injection of D-galactose (48mg / kg.d), the 6-week brain aging group, at the same time, was given "ginsenoside" by gavage for 6 weeks

[0127] (30mg / kg.d)

[0128] The control group received subcutaneous injection of normal saline (2ml / kg.d) for 6 weeks

[0129] * The ginsenosides used in this example are selected from Rb1, Rb2, Rc, Rd, Re,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention proposes the novel use of ginsenoside in preparing medicine. The prepared medicine is used in used in preventing and reducing damage of nerve cell caused by compressive stress from external environment, maintaining the activity of nerve cell, resisting cerebral senility and strengthening memory.

Description

Field of Invention [0001] The invention relates to a new use of ginsenosides in the pharmaceutical field. The substance has the function of resisting and reducing the damage of nerve cells caused by external environmental pressure and protecting the vitality of nerve cells. It is used to resist brain aging and enhance memory. Background of the Invention [0002] In the early 1990s, on the basis of domestic and foreign research, Chinese scholars carried out in-depth separation and identification of saponins from ginseng roots and their aerial parts, and systematically carried out the metabolic chemistry, semi-synthesis, alkaline hydrolysis and analytical methods of monomer saponins. In the study, 10 new saponins were obtained from ginseng stems and leaves, which were 20(R)-ginsenoside-Rh2, -Rh3, -La, -F4, 25-hydroxy-ginsenoside-Rg2, 25-hydroxy-ginseng Saponins-Rh1, -Ia, -Ib, koryoginsenoside-R1 and -R2 (1~3). So far, more than 40 kinds of saponins have been isolated and de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P25/00A61P43/00
Inventor 吴超群郭红卫钟翠平高瑞兰
Owner 上海复旦金科生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com